UPDATE 3-Early approval of Alnylam's gene-silencing drug in question


Alnylam Pharmaceuticals Inc said on Thursday early data from its trial for gene-silencing drug givosiran showed it was effective, but added it might have to hold off on earlier plans to seek an accelerated approval from U.S. regulators. Shares in the Cambridge, Massachusetts-based developer fell nearly 4 percent to $87.72, after rising slightly in premarket trade.



from Biotech News